What insurance policy changes affect code F50.00?

There are 5 tracked policy changes affecting code F50.00, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code F50.00?

Payers that have issued tracked updates for code F50.00 include: Aetna.

How do I get notified when code F50.00 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code F50.00. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code F50.00?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

F50.00 Insurance Policy Changes

ICD-10 F50.00 is officially defined as "Anorexia nervosa, unspecified." code F50.00 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code F50.00 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 19, 2026Medium impact
Zoledronic Acid (CPB 0524, reviewed 2026-02-12)
Aetna's clinical policy bulletin covers zoledronic acid for commercial medical plans. Zoledronic acid 5 mg (Reclast or generic) is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget's disease of bone, and treatment-related bone loss in men with prostate cancer receiving androgen deprivation therapy, when the listed criteria are met. Zoledronic acid 4 mg (formerly branded Zometa) is considered medically necessary for bone metastases from a solid tumor, certain breast cancer indications, hypercalcemia of malignancy, Langerhans cell histiocytosis with bone disease, multiple myeloma, and systemic mastocytosis with osteopenia or osteoporosis. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Nutritional Counseling (CPB 0049, reviewed 2026-03-10)
Aetna considers nutritional counseling a medically necessary preventive service for children and adults who are obese, and for adults who are overweight and have hypertension, dyslipidemia, impaired fasting glucose, or metabolic syndrome, when a provider recognized under the plan furnishes it. Aetna also considers counseling medically necessary for other chronic conditions where dietary adjustment has a therapeutic role, including diabetes, eating disorders, gastrointestinal disorders, hypertension, kidney disease, and seizures (ketogenic diet). Aetna considers counseling of unproven value for asthma, attention-deficit hyperactivity disorder, and chronic fatigue syndrome, and considers the NutrEval test experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)
Aetna considers quantitative EEG (brain mapping, also called BEAM) medically necessary only as an adjunct to traditional EEG for specified uses, including ambulatory EEG recording to facilitate later expert visual interpretation, continuous EEG monitoring by frequency-trending in the operating room or ICU, and topographic voltage and dipole analysis in pre-surgical evaluations for intractable epilepsy. Aetna considers quantitative EEG experimental, investigational or unproven for all other indications, including attention disorders, autism spectrum disorders, depression, schizophrenia, bipolar disorder, insomnia, fibromyalgia, post-traumatic stress disorder and post-concussion syndrome. The BrainScope One System (Ahead 300) is considered experimental, investigational or unproven for evaluation of concussion or traumatic brain injury.
Aetna · Identified Aug 13, 2026Medium impact
Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)
Aetna considers professional services for pediatric intensive feeding programs medically necessary for infants and children with complex feeding and swallowing disorders when an interdisciplinary team provides the care and every listed condition is met. Those conditions include behavior problems interfering with feeding, a documented diagnosis-specific treatment plan with estimated length of treatment, medical causes of failure to thrive treated without resolving the feeding problem, physician coordination and oversight, one of the listed feeding problems, and no response to initial treatment by a single discipline over a 2-month period. Other indications, such as childhood obesity and Prader-Willi syndrome, are considered experimental, investigational, or unproven, and electrical stimulation for swallowing or feeding disorders is also considered experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Eating Disorders (CPB 0511, reviewed 2026-08-04)
Aetna considers these services medically necessary for members with anorexia nervosa or bulimia nervosa: medical evaluation with history and physical examination, psychiatric or psychological consultation and testing, blood count and serum chemistry, albumin and prealbumin, liver function tests, electrocardiography, urinalysis, thyroid function testing (TSH), bone density measurement for evaluation of anorexic members, and LH, FSH and estradiol for women with amenorrhea or oligomenorrhea. Treatment considered medically necessary includes nutritional counseling, psychotherapy (such as cognitive behavioral therapy, dialectical behavior therapy, family-based, interpersonal and psychodynamic psychotherapy), and enteral nutrition as a last resort for the treatment of anorexia nervosa. Self-administered pharmacotherapies are managed under the pharmacy benefit. The policy lists CPT and HCPCS codes covered if selection criteria are met, and codes not covered for the indications listed. Aetna considers a long list of services experimental, investigational or unproven for anorexia nervosa, bulimia nervosa and binge-eating disorder, including brain imaging, EEG, routine screening of asymptomatic adolescents and adults for eating disorders, acupuncture, deep brain stimulation, electroconvulsive therapy, repetitive transcranial magnetic stimulation, cannabinoids, oxytocin and ghrelin agonists.

Watch F50.00

Get one email when a payer policy names F50.00, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Zoledronic Acid (CPB 0524, reviewed 2026-02-12)

Nutritional Counseling (CPB 0049, reviewed 2026-03-10)

Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)

Pediatric Intensive Feeding Programs (CPB 0809, reviewed 2025-12-11)

Eating Disorders (CPB 0511, reviewed 2026-08-04)

What insurance policy changes affect code F50.00?

Which payers have updated policy for code F50.00?

How do I get notified when code F50.00 policy changes?

Why do payers change policies for code F50.00?